GoodRx Holdings heads into its Q1 2026 earnings report with bears moving in fast — and the stock ripping higher despite them.
The short interest story here is genuinely striking. Short positions have jumped 59% over the past week to 12.3% of the free float, nearly doubling from the ~8% range that held steady through most of April. That acceleration is sharp: the move from May 1 to May 5 alone added nearly five million shares to the short book. The ORTEX short score reached 71.3 — a new high for the series in this snapshot — up from 56 just four sessions earlier. The borrow market has tightened alongside it: availability has dropped to its tightest level of the past 52 weeks, with cost to borrow climbing 22% on the week to 0.75%. That said, borrowing costs in absolute terms remain low, meaning the demand for shorts is rising but the borrow market is not yet under severe stress.
Options traders are telling a different story. The put/call ratio is running at 0.20 — below its 20-day average of 0.21 and well clear of its 52-week high of 0.32. That places options sentiment marginally on the bullish side of neutral, not the defensive posture you might expect given the short interest surge. The contrast is notable: one set of investors is pressing shorts aggressively, while the options market carries no particular hedge premium into the print.
The bull and bear debate is set against a backdrop of relentlessly negative analyst revisions, though the most recent cluster of cuts dates to early March — now more than two months ago and flagged here as stale. After Q4 results, Wells Fargo, Citi, Goldman Sachs, Mizuho, and JP Morgan all trimmed targets or ratings, with JP Morgan's Lisa Gill downgrading to Neutral. The mean price target around that time was $2.97 against a stock now trading at $2.57 — a discount that is narrow enough to be plausible but suggests limited upside in most Street models. Bulls still holding Buy ratings at Citi point to GoodRx's prescription cost platform as a durable consumer health asset. Bears, led by Barclays at Underweight, focus on intensifying competition and stalling user growth. The stock's valuation is not obviously stretched — EV/EBITDA is running near 4.8x and PE near 7.6x — which may explain why options traders haven't rushed for cover.
Price action adds another layer of tension. GDRX has rallied 25% over the past month and 12% in the past week alone, closing at $2.57 on May 6. That advance came directly into a short interest surge — a combination that can amplify moves in either direction. Past earnings reactions have been severe: the February 2026 print produced a one-day drop of 24%, followed by a five-day loss of 7%. The March 2026 event reversed that, with a one-day gain of 11% and a five-day gain of 26%. Peers in health technology moved broadly higher on the week — TDOC up 14%, LFMD up 19%, AMWL up 16% — suggesting sector tailwinds have helped carry GDRX into this print.
Today's report is therefore a direct test of whether the recent stock re-rating reflects genuine operational improvement, or whether the short sellers who have been piling in over the past week are ahead of results that disappoint a market now priced for recovery.
See the live data behind this article on ORTEX.
Open GDRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
